ImmunoPrecise Antibodies (IPA) said Tuesday its BioStrand unit is partnering with PGxAI to create an adaptive artificial intelligence model to predict patient responses to drugs, transforming personalized medicine.
Financial details of the partnership weren't disclosed.
PGxAI will utilize BioStrand's foundation AI model LENSai to develop an AI model for pharmacogenomics, the study of how genetic variations affect drug response, ImmunoPrecise said.
Shares of ImmunoPrecise were up 3% in recent trading.
Price: 1.03, Change: +0.03, Percent Change: +3.00
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments